| Schedule of Segment Loss Including Significant Segment Expenses |
The table below is a summary of the segment loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
|
(in thousands) |
|
Program expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Navacaprant (NMRA-140) program |
|
$ |
(13,308 |
) |
|
$ |
(22,257 |
) |
|
$ |
(34,218 |
) |
|
$ |
(46,750 |
) |
M4 PAM programs |
|
|
(1,947 |
) |
|
|
(2,370 |
) |
|
|
(4,920 |
) |
|
|
(5,252 |
) |
NMRA-511 program |
|
|
(1,075 |
) |
|
|
(2,257 |
) |
|
|
(2,293 |
) |
|
|
(4,837 |
) |
Preclinical programs |
|
|
(3,022 |
) |
|
|
(1,459 |
) |
|
|
(5,704 |
) |
|
|
(2,461 |
) |
Research and development personnel-related costs |
|
|
(8,786 |
) |
|
|
(7,617 |
) |
|
|
(18,165 |
) |
|
|
(19,943 |
) |
General and administrative expense |
|
|
(12,907 |
) |
|
|
(15,316 |
) |
|
|
(27,173 |
) |
|
|
(34,101 |
) |
Interest income |
|
|
935 |
|
|
|
2,250 |
|
|
|
2,166 |
|
|
|
5,324 |
|
Interest expense |
|
|
(1,820 |
) |
|
|
(436 |
) |
|
|
(3,674 |
) |
|
|
(436 |
) |
Other segment items(1) |
|
|
(1,152 |
) |
|
|
(3,269 |
) |
|
|
(2,559 |
) |
|
|
(12,267 |
) |
Net loss |
|
$ |
(43,082 |
) |
|
$ |
(52,731 |
) |
|
$ |
(96,540 |
) |
|
$ |
(120,723 |
) |
(1) Includes other research and development costs, provision for income taxes, and other income (expense).
|